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Background: To explore trends in the incidence and survival of patients with intrahepatic cholangiocar-
cinoma (ICC) an unselected population in Western Europe was studied.
Methods: Between 1989 and 2009, all patients newly diagnosed with ICC were selected from the
Netherlands Cancer Registry (n = 809). Trends in incidence, treatment and relative survival were calcu-
lated according to gender and age. Follow-up for vital status was complete until 1st January 2010.
Results: The incidence rates of ICC increased significantly between 1999 and 2009, especially in the age
group 45–59 years [estimated annual percentage change +3.0%, 95% confidence interval (CI) 0.2–5.8]. In
the other age groups ICC incidence remained stable. Patients diagnosed with Tumour Lymph Node
Metastasis (TNM) stage I mainly underwent surgery (68%), and the majority of the patients with stage II,
III and IV received best supportive care (73%). One-year relative survival for patients with ICC increased
significantly from 24% in 1989–1994 to 28% in 2005–2009 (P = 0.03), and corresponding 3-year relative
survival improved from 4% to 8% (P = 0.02). Three-month and 1-year relative survival for patients with ICC
receiving surgery was 91% and 71%, respectively.
Discussion: Between 1999 and 2009, the incidence of ICC rose, especially in the age group 45–59
years, suggesting aetiological influences. Survival rates have improved during the study period.
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Introduction
Intrahepatic cholangiocarcinoma (ICC) malignancy arising from
the ductal epithelium of the biliary tree has a poor prognosis.1,2
Perhaps because ICC is rare diagnosis, few reports on the epide-
miology of ICC are available, and information on survival trends
of ICC patients are only available from single institution case
series, mostly describing patients who underwent a surgical
resection.3–5 Such studies do not reflect the outcome of an unse-
lected group of patients. Because improved computed tomogra-
phy (CT) and high-resolution magnetic resonance imaging (MRI)
of the liver have facilitated the diagnosis of liver malignancies,
changes in ICC detection and survival are expected to occur as is
reported by two studies from the United States.6,7 Therefore, a
population-based study in the Netherlands of all patients diag-
nosed with ICC between 1989 and 2009 was performed and trends
in incidence and survival according to gender, age and treatment
were studied.
Methods
Data collection
Incidence and treatment data on ICC (ICD-10 code C22.1) from
the period 1989–2009 were provided by the population-based
Netherlands Cancer Registry (NCR) which is managed by the
Comprehensive Cancer Centres the Netherlands and South.8 The
NCR is based on notification of all newly diagnosed malignancies
in the Netherlands by the automated pathological archive
(PALGA). Additional sources are the national registry of hospital
discharges and radiotherapy institutions. Information on patient
characteristics, such as gender and date of birth and tumour char-
acteristics, such as date of diagnosis, localization [(International
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Classification of Diseases for Oncology (ICD-O-3)], histology,
stage [Tumour Lymph Node Metastasis (TNM) classification] and
primary treatment, are obtained routinely from the medical
records.9 The quality of the data is high, as a result of thorough
training of the data managers, good access to care and computer-
ized consistency checks. The infrastructure of the Netherlands
health care system and the notification procedure used have made
it possible to establish a cancer registry in which completeness is
estimated to be at least 95% of the country.10,11 In the case of
multiple tumours, the same rules were applied as those recom-
mended by the International Association of Cancer Registries.12
The information on vital status was initially obtained from
municipal registries and from 1995 onwards from the nationwide
population registries network, providing complete coverage of all
deceased Dutch residents.
ICC arises from the intrahepatic bile duct epithelium whereas
extra-hepatic cholangiocarcinomas and Klatskin tumours involve
the biliary tree within the hepatoduodenal ligament.13 To limit
potential misclassification bias, patients with a non-classified
tumour (histological or clinical), an extra-hepatic cholangiocar-
cinoma or a Klatskin tumour were excluded (n = 301).
Age was divided into five groups, i.e. <30, 30–44, 45–59, 60–74
and75 years. The study period was divided into four categories,
namely 1989–1994, 1995–1999, 2000–2004 and 2005–2009. TNM
stage was determined post-operatively and clinical stage was used
in case pathological TNM was missing. Treatment was scored as
follows: surgery with curative intent including a partial liver resec-
tion, chemotherapy (systemic or regional)/ irradiation therapy or
no specific anti-cancer therapy, i.e. best supportive care.
Patients younger than 15 years and older than 95 years were
excluded from the survival analysis, as well as patients who had the
diagnosis made at autopsy.
Statistical analyses
Annual incidence rates for the period 1989–2009 were calculated
per 100 000 person-years, using the annual mid-year population
size as obtained from Statistics Netherlands. Rates were age stan-
dardized to the European standard population [European Stan-
dardized Rates (ESR)]. Changes were evaluated by calculating the
estimated annual percentage change (EAPC) and the correspond-
ing 95% confidence interval (95% CI). Data regarding mortality
trends were not available. Follow-up of vital status of all patients
was calculated as the time from diagnosis to death, lost to
follow-up or until the 1st of January 2010. The cohort-based
method for relative survival analysis was used. Survival trends
within 1989–2009 were evaluated using a Poisson regression
model.14 SAS software (SAS system 9.2; SAS Institute, Cary, NC,
USA) was used to perform the statistical analyses.
Results
Incidence
During the period 1989 to 2009, 809 patients were diagnosed with
ICC of whom 785 (97%) were pathologically confirmed. The
median age was 68 years (range 23–95) which did not change over
time. The age-standardized incidence rate (ESR per 100 000) was
similar for males and females. The overall incidence of ICC
decreased from 0.22 per 100 000 in 1989 to 0.12 in 1999 (EAPC
-5.0%, 95% CI -9.2, -0.7) and thereafter increased to 0.35 per
100 000 in 2009 (EAPC +9.4%, 95% CI 4.6, 14.3). Figure 1 shows
the incidence rates by gender.
Figure 2 displays in five age groups the trends of ICC for both
genders combined. A significantly increasing trend was observed
in the age group 45–59 years (EAPC +3.0%, 95% confidence inter-
val 0.2–5.8). The average annual number of new patients diag-
nosed with ICC (both sexes) was 0.3 (range 0–1) patients for the
age group 0–29 years, 2.9 (range 0–8) patients for 30–44 years, 9.2
(range 3–16) patients for 45–59 years, 16.8 (range 4–31) patients
for 60–74 years and 11.4 (range 6–22) patients for age 75 years and
over.
Treatment
Between 1989 and 2009, data regarding treatment and TNM stage
were available in 511 patients and are summarized in Table 1.
Survival
Data regarding survival between 1989 and 2009 were available in
760 patients and missing in 49 patients. The relative survival rates
for patients with an ICC between 1989 and 2009 improved
(Table 2). The short-term (3, 6 months and 1 year) survival pro-
portions for ICC patients who underwent surgery were 91%, 81%
and 71%, respectively. The long-term (3-year and 5-year) survival
proportions for ICC patients who underwent surgery were 40%
and 34%, respectively. For ICC patients receiving chemotherapy
and/or irradiation corresponding short-term numbers were 93%,
74% and 51%, respectively. For ICC patients receiving no anti-
cancer therapy the short-term rates were 39%, 23% and 12%,
respectively. There were no long-term survivors.
Discussion
Incidence
This population-based study demonstrates an increase in the inci-
dence of ICC in the Netherlands between 1999–2009 and improve-
ments in survival. The increasing ICC incidence confirms and
expands the previous findings on hepatocellular carcinoma (HCC)
reported in low endemic areas.6,15 The question is whether the
rising incidence rate of ICC is a true increase or a reflection of
improved diagnostic tests resulting in more detected tumours [e.g.
MRI, multiphase CT, positron emission tomography (PET) scan
and endoscopic retrograde cholangiopancreatography] which only
became available at larger scale since 2002 in the Netherlands. In
the absence of generally used serum markers better imaging tech-
niques might cause an increased detection or reclassification of
hepatobiliary tumours. ICC arises from the intrahepatic bile duct
epithelium while extra-hepatic cholangiocarcinomas and Klatskin
tumours involve the biliary tree within the hepatoduodenal liga-
ment.13 To limit potential misclassification bias, patients with a
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Figure 1 Trends (3-year moving averages) in age-standardized incidence rates (ESR) for intrahepatic cholangiocarcinoma (ICC) according to
gender, in the Netherlands, 1989–2009
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Figure 2 Trends (3-year moving averages) in age-specific incidence rates (ESR) for intrahepatic cholangiocarcinoma (ICC) in the Netherlands,
1989–2009
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non-classified tumour (histologically or clinically), an extra-
hepatic cholangiocarcinoma or a Klatskin tumour were not
included. The number of patients (97%) with ICC histologically
confirmed is therefore rather high.
Tumours previously described as unclassified might be classi-
fied as ICC today.16 In case of misdiagnosis one would expect the
incidence of at least one hepatobiliary tumour to decrease upon
the rise of ICC. This has not happened, as the incidence of HCC
also increased, and therefore the increasing incidence of ICC
seems to be real.15 The increased detection of cancer is usually
associated with an increase in the proportion of patients with
early-stage cancers in all age groups. Therefore, it would have been
interesting to study trends according to disease stage. Unfortu-
nately as a result of changes in TNM-staging classification during
the study period, it was not possible to draw any conclusion from
trends by disease stage.
If the increase in ICC is a true reflection of an increased fre-
quency, as can be suggested, the reason for this increase is
unknown.6,17 Several medical conditions are potentially related
to ICC, including biliary cirrhosis, cholecystitis, alcoholic liver
disease, liver cirrhosis, type II diabetes mellitus, chronic pancre-
atitis, hepatitis C viral infection (HCV), hepatitis B viral infection
(HBV), obesity, non-alcohol fatty liver disease (NAFLD), non-
alcoholic steatohepatitis (NASH), primary sclerosing cholangitis
(PSC), primary biliary cirrhosis (PBC) and inflammatory bowel
diseases including ulcerative colitis.18 One possible explanation,
for the observed increases, supported by recent studies, might be
an increase in HCV- and/or HBV-related ICC.19 However, details
on presence of HCV and/or HBV in this population were not
available, preventing us from further investigating these hypoth-
eses. Chronic inflammation, cholestasis and chronic liver damage
are associated with malignant transformation of the biliary epi-
thelium.18 Perhaps the increasing incidence of ICC might be influ-
enced by an increasing prevalence of PSC.6,16,17 PSC-related
cancers are reported to peak after the 4th or 5th decade of life.18,20
In this study, the rising incidence occurred predominantly in
patients aged from 45 to 59 years which is possibly explained by an
increasing prevalence of PSC.7 Although data regarding changes in
prevalence of risk factors for ICC were not analysed, the increasing
incidence of ICC is likely to be a true phenomenon rather than a
reflection of improved diagnosis or a detection bias.11 Other
explanations of the observed trends may be misclassification and
changes in registration and/or diagnostic practices over time,
therefore these data need to be interpreted with caution. The
distinction between intrahepatic and extrahepatic cholangiocar-
cinoma is somewhat arbitrary, especially if it concerns a hilar
cholangiocarcinoma. But, as extrahepatic cholangiocarcinoma in
the Netherlands is five to six times more common than ICC,
misclassification of only a small proportion of the extrahepatic
tumours as intrahepatic has a relatively large influence on the
incidence of ICC.
Treatment and survival
Tumour resection is the only potential cure for ICC, mostly
patients in TNM stage I are able to receive this therapy. Pre-
operative evaluation includes an assessment of patients’ fitness for
surgery, evaluation of the presence of metastatic disease and anal-
ysing the possibility to create a resection margin free from can-
cer.21 If any of these conditions are not fulfilled, surgical therapy is
not indicated and palliative modalities are recommended.
Aljiffry et al. reviewed the literature according to outcome after
surgical resection for ICC and found 5-year survival rates ranging
from 15% to 40%, similar to the 5-year survival rate in this study
of 34%.13 Because only a few patients received surgery, trends in
survival over time could not be calculated for surgery.
After a complete surgical resection, a strategy aimed at optimiz-
ing local control with post-operative radiation alone or in com-
bination with chemotherapy may theoretically provide a benefit.22
However, the available literature consists mainly of an uncon-
trolled small series, and many reports consist of a mix of bile duct
cancers, gallbladder cancer, ampullary cancer, and either pancre-
atic or hepatocellular cancers; as a result, the benefit of any type of
adjuvant therapy remains uncertain.5,23 In general, no single drug
or combination has consistently led to objective tumour shrinkage
or an increased median survival beyond the expected 8 to 15
months.5,23 It is interesting to see that patients who received
chemotherapy/irradiation had a similar short-term survival rate,
Table 1 Treatment according to Tumour Lymph Node Metastasis
(TNM) stage in patients with intrahepatic cholangiocarcinoma in the
Netherlands between 1989 and 2009
TNM stage N Treatment n (%)
Surgery Chemotherapy
and/or irradiationa
No specific
anti-cancer
therapy
I 31 21 (68) 0 (0) 10 (32)
II 47 15 (32) 4 (8) 28 (60)
III 121 35 (29) 19 (16) 67 (55)
IV 312 7 (2) 49 (16) 256 (82)
aPatients were treated according to hospital protocols, no exact chemo-
therapy and/or irradiation treatment regimes were available from the
registry over time.
Table 2 Relative survival of patients with intrahepatic cholangiocar-
cinoma in the Netherlands, since 1989 according to period of
diagnosis
Period of
diagnosis
N Survival % (SE)
3 months 6 months 1 year 3 years
1989–1994 174 50 (3.9) 33 (3.7) 24 (3.3) 4 (1.6)
1995–1999 137 45 (4.3) 30 (4.0) 17 (3.2) 7 (2.3)
2000–2004 181 55 (3.7) 37 (3.6) 24 (3.2) 11 (2.4)
2005–2009 268 56 (3.1) 41 (3.1) 28 (2.9) 8 (2.6)
P-value for trend 0.04 0.02 0.03 0.02
SE, standard error.
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especially at 3 and 6 months (93% and 74%) compared with
patients who underwent surgery (91% and 81%). Studies on
palliative chemotherapy on patients with ICC have reported a
median survival time between 6 and 15 months.13 The survival
benefit for patients able to receive surgery was increased with
duration of follow-up, as the long-term survival in patients receiv-
ing surgery is much better compared with patients receiving
chemotherapy/irradiation.
As the benefit of any type of adjuvant therapy remains doubt-
ful, the improved survival can be attributed to improved palliative
treatments (stenting and drainage), improved overall supportive
medical care, or both.
The improved survival could indicate lead-time bias related to
early detection as patients with associated factors are controlled
more often. For instance patients with PSC have a lifetime risk of
ICC which ranges from 8% to 20% and therefore these data need
to be interpreted with caution.16
In conclusion, this population-based analysis appears to dem-
onstrate an increasing incidence of ICC since 1999. Overall sur-
vival of patients with ICC appears to be improved, suggesting
possible influences of improved imaging techniques, a better
patient selection for surgery or improved surgical techniques. As a
result of limitations both these statements should be interpreted
with caution. This study demonstrates that although improve-
ments in ICC survival were achieved over time, patients with these
tumours continue to have a very poor prognosis. In spite of several
advances over the last decades, an ample opportunity for improve-
ment still remains.
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